Development of interventions for the secondary prevention of Alzheimer's dementia: The European Prevention of Alzheimer's Dementia (EPAD) project

The Lancet Psychiatry

Volumn 3, Issue 2, 2016, Pages 179-186

  Ritchie, Craig W ^a   Molinuevo, José Luis ^b   Truyen, Luc ^c   Satlin, Andrew ^d   Van der Geyten, Serge ^e   Lovestone, Simon ^f  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Barcelonaßeta Brain Research Center   (Spain)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d EISAI INC   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL ASSESSMENT TOOL; DEMENTIA; DISEASE MARKER; DISEASE REGISTRY; EUROPEAN; EUROPEAN PREVENTION OF ALZHEIMER DEMENTIA PROJECT; HEALTH CARE ACCESS; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MEDICAL ETHICS; MEDICAL SOCIETY; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; SECONDARY PREVENTION; EUROPE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALZHEIMER DISEASE; DEMENTIA; EUROPE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 84957440529     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00454-X     Document Type: Review

References (11)

1. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010, 9:702-716.
2. Dementia: a public health priority 2012, WHO and Alzheimer's Disease International, World Health Organization, Geneva, (accessed June 23, 2015). http://www.who.int/mental_health/publications/dementia_report_2012/en/.
3. Khachaturian ZS Perspectives on Alzheimer's disease: past, present and future. Alzheimer's disease-modernizing concept, biological diagnosis and therapy 2012, 179-188. Karger, Basel. M.C. Carrillo, H. Hampel (Eds.).
4. Ritchie CW, Ritchie K The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. BMJ Open 2012, 2:e001893.
5. Study for cognitive and genetic characterization of a 45-65 years old population (accessed June 26, 2015). https://clinicaltrials.gov/ct2/show/NCT01835717.
6. Vaudano E, Vannieuwenhuyse B, Van der Geyten S, et al. Boosting translational research on Alzheimer's disease in Europe: the Innovative Medicine Initiative Alzheimer's disease research platform. Alzheimers Dement 2015, 11:1121-1122.
7. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009, 86:97-100.
8. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2012, 8(suppl 1):S1-68.
9. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009, 21:672-687.
10. Lovestone S, Francis P, Kloszewska I, et al. AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 2009, 1180:36-46.
11. Becker RE, Seeman MV, Greig NH, et al. What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?. Lancet Psychiatry 2015, 2:756-764.